| Effect of Recombinant Human Erythropoietin on the Anemia of Premature Infants |
|
Young Ah Lee, Ki Soo Kim, Young Seo Park, Hyung Nam Moon, Chang Yee Hong |
|
Department of Pediatrics, Ulsan University Medical School, and Asan medical Center, Seoul, Korea |
| 미숙아 빈혈에서 Recombinant Human Erythropoietin의 효과 |
|
이영아, 김기수, 박영서, 문형남, 홍창의 |
|
울산대학교 의과대학 아산재단 서울중앙병원 소아과학교실 |
|
|
|
|
| Abstract |
Purpose
: To determine whether the prophylactic treatment with recombinant human
erythropoietin(rHuEPO) for the anemia of prematurity would reduce the need for blood
transfusions.
Methods
: We randomly assigned 17 premature infants to therHuEPO group and the
control group. For the rHuEPO group (n=9, birth weight=1210¡¾156 g, gestational
age=31.7¡¾1.9wk), rHuEPO (400U/kg) was given three times a week for 4 weeks, plus
iron (8 mg/kg/day) and vitamin E (25 IU/day). The same amount of vitamin E was
only given for the control group (n=8,birth weight=1266¡¾204 g, gestational age=30.0¡¾1.9wk).
Results
: Reticulocyte counts and hematocrit values were higher in the rHuEPO
group than the control group at the 4 week of study (10.0¡¾1.5% vs. 5.5¡¾2.1%:
p<0.05 and 25.6¡¾4.0% vs. 31.0¡¾1.5%: p<0.05). Also, hemoglobin F were higher in the
rHuEPO group than the control group at the 4 week of study (76.2¡¾8.1% vs. 27.2¡¾33.3
%: p<0.05). The rHuEPO treatment group required fewer blood transfusions during the
study period (1.25 vs. 0.11: p<0.05). And the complications such as leukopenia, thrombocytosis and infection did not develop during the study period. There was no
evidence of irondeficiency state in the both groups.
Conclusion
: The rHuEPO treatment, in combination with iron supplementation, prevented the anemia of prematurity and reduced the need for blood transfusion in the
prematureinfants. |
| Key Words:
Recombinant Human Erythropoietin, Anemia of Prematurity |
|
PDF Links
Download Citation
